 Breda, the Netherlands Ghent, Belgium argenx Euronext Nasdaq: ARGX, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of a global offering of ordinary shares represented by American Depository Shares ADSs in the United States and certain other countries outside of European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area. The Company anticipates total gross proceeds of approximately 750.0 million approximately 682.4 million from the sale of 2,584,138 ADSs at a price of 205.00 per ADS and the sale of 1,074,377 ordinary shares at a price of 186.52 per ordinary share. 